Archives for


Possible Chemotherapy Replacement From Dana-Farber Cancer Institute in Boston

 Newly reported data for AstraZeneca Plc (AZN)’s experimental cancer treatments “gives credibility” to the drugmaker’s forecast of $45 billion in annual revenue by 2023, according to Chief Executive Officer Pascal Soriot. The release of information on AstraZeneca’s new medicines this weekend at the American Society of Clinical Oncology meeting should lessen skepticism about the prediction,

Pfizer Raises AstraZeneca Offer to $106.5 Billion

 Pfizer Inc. (PFE) sweetened its bid for AstraZeneca Plc (AZN) to about 63.1 billion pounds ($106.5 billion), aiming to bring the U.K.’s second-biggest drugmaker to the negotiating table. The offer values AstraZeneca at 50 pounds a share in cash and stock, New York-based Pfizer said in statement today. The London-based company rejected a proposal of